

# A Systematic Review of the Frequency of Regulatory T Cells in Hepatitis B and Hepatitis C

Tri Nugraha Susilawati\*, Atik Susianto\*\*

\*Department of Microbiology, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia

\*\* Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia

## Corresponding author:

Tri Nugraha Susilawati, Department of Microbiology, Faculty of Medicine, Universitas Sebelas Maret, Jl. IR. Sutami 36 A Surakarta Indonesia. Phone: +62-271-632489; Facsimile: +62-271-637400. E-mail: tri.susilawati@staff.uns.ac.id

## ABSTRACT

**Background:** Regulatory T cells (Tregs) play an important role in sustaining the hepatitis B and C viruses (HBV and HCV) persistence and protecting the liver tissues from cytokine-associated detrimental effects through unclear mechanisms. This paper aims to review the frequency of Tregs during the course of HBV and HCV infection.

**Method:** Electronic databases were searched to identify studies investigated the frequency of intrahepatic and peripheral Tregs of the patients infected with HBV and/or HCV.

**Results:** The majority of studies reported the increase of intrahepatic and peripheral Tregs in acute and chronic infection of HBV and HCV. The decrease of peripheral Tregs occurred in patients with chronic hepatitis B who respond to interferon  $\alpha$  or nucleos(t)ide analogues treatment as well as those with chronic hepatitis C who were treated with interferon, ribavirin or liver transplantation.

**Conclusion:** Infection with HBV and HCV appears to induce the production of Tregs in blood and hepatocytes whereas treatment may decrease Tregs levels. As the optimum balance between regulatory and effector T during HBV and HCV infection is crucial for preventing liver damage, further studies should be directed on the development of Tregs during HBV and HCV infection as well as their involvement in immunomodulatory strategies for combating HBV and HCV.

**Keywords:** T-lymphocytes, regulatory, hepatitis B, hepatitis C

## ABSTRAK

**Latar belakang:** Regulatory T cells (Tregs) memainkan peranan penting dalam menjaga keberlangsungan infeksi virus hepatitis B dan C (HBV dan HCV) serta melindungi jaringan hati dari kerusakan yang diakibatkan oleh sitokin melalui mekanisme yang belum diketahui secara pasti. Artikel ini bertujuan untuk menelaah frekuensi Tregs selama perjalanan infeksi HBV dan HCV.

**Metode:** Penulis mencari artikel penelitian di basis data elektronik. Artikel yang diidentifikasi adalah studi yang menginvestigasi frekuensi Treg di hati dan di sirkulasi darah dari pasien-pasien yang terinfeksi HBV dan/ atau HCV.

**Hasil:** Sebagian besar artikel melaporkan adanya peningkatan Tregs intrahepatik dan perifer pada infeksi HBV dan HCV, baik akut maupun kronik. Penurunan frekuensi Treg di perifer terjadi pada pasien dengan hepatitis B kronik yang berespon terhadap pengobatan interferon  $\alpha$  atau analog nucleos(t)ida, demikian pula pada penderita hepatitis C yang diterapi dengan interferon, ribavirin atau transplantasi hati.

**Simpulan:** Infeksi HBV dan HCV tampaknya menginduksi produksi Treg di darah dan sel-sel hati sedangkan pengobatan dapat menurunkan jumlah Treg. Keseimbangan yang optimal antara Treg dan T efektor selama infeksi HBV dan HCV penting untuk mencegah kerusakan hati. Oleh karena itu, diperlukan penelitian-penelitian lanjutan terkait perkembangan Treg selama infeksi HBV dan HCV serta keterlibatannya dalam strategi imunomodulasi untuk melawan HBV dan HCV.

**Kata kunci:** limfosit T, regulatory, hepatitis B, hepatitis C

## INTRODUCTION

Hepatitis B and hepatitis C are important public health issues with increasing numbers of patients despite the immense efforts to control the transmission. The World Health Organization (WHO) estimated that in 2015, there were 257 million people have chronic HBV infection and 71 million cases of chronic HCV infection.<sup>1</sup> Whilst antiviral and immunological treatments are available and on trials, none can eliminate the viruses and prevent the chronic sequel of HBV and HCV infection. Thus, it poses a substantial threat to the chronically infected patients as the infection cannot be totally cured, leading to terminal illness due to liver failure and carcinoma. The long-term morbidity in hepatitis B and C cases are clearly associated with significant clinical and economic burden.<sup>2</sup>

The rules of cellular and humoral immunity in hepatitis B and C have been widely studied but limited data exist regarding the role of regulatory T cells (Tregs) in the course of these illnesses. The majority of studies on hepatitis B immunity have frequently reported Natural Killer (NK), CD4<sup>+</sup> cells, CD8<sup>+</sup> cells, and antibodies to HBV. As for hepatitis C, previous reports have primarily focused on interferon response, antibodies HCV and cytotoxic T lymphocytes. Jung and Shin suggested that Tregs are involved in the disease chronicity by maintaining viral persistence and protecting the liver tissues from cytokine-associated detrimental effects.<sup>3</sup>

This paper presents a review of the available literature reporting studies that measure the frequency of Tregs in various states of HBV and HCV infection.

## METHOD

On 14 August 2017, literature were searched in PubMed, Scopus, Web of Science and Medline databases using the following terms: “regulatory T cell [Title/Abstract]” AND “hepatitis [Title/Abstract]” AND “infection”. The results were reviewed systematically according to PRISMA guidance.<sup>4</sup>

Inclusion criteria included journal articles published in English that described Tregs in HBV and HCV research. Review articles were excluded as well as case reports and studies that focused on children, malignancy, inflammatory or autoimmune diseases and those including other pathogens such as co-infection with human immunodeficiency virus (HIV). The articles identified were reviewed systematically and references of the included papers were also examined.

## RESULTS

The initial search identified 224 articles. After removing duplicate articles, 129 articles remained, of which 35 were removed after reading their titles and/or abstracts. The entire texts of the 94 remaining articles were reviewed, of which 37 passed all exclusion criteria and met all inclusion criteria. After evaluating the references, listed in 37 articles above, 18 articles were added to the review resulting in the total of 55 articles being analysed. (Figure 1)

Table 1 summarizes the 55 studies evaluating Tregs levels at different stages of HBV or HCV infection. The majority of studies involved chronically infected patients. Only two studies reported Tregs level in acute hepatitis B (AHB) and the other two studied acute hepatitis C (AHC).<sup>5,6,31,32</sup> Five studies reported Tregs level in patients with HBV-related acute-on-chronic liver failure (ACLF).<sup>9,10,21-23</sup>

During the acute stage of HBV infection, the frequency of peripheral Tregs remains normal whilst HCV caused an immediate increase of Tregs level in circulation. Most patients with chronic HBV and HCV infection had an increase of Tregs level in their blood circulation and liver. The treatment of chronic hepatitis B could reduce Tregs frequency but in patients with chronic hepatitis C, the results were not consistent.

## DISCUSSION

Overall, there are 20 longitudinal studies and 34 cross-sectional studies. One study performed both longitudinal and cross-sectional approaches.<sup>47</sup> For the


Table 1. The study of Tregs frequency in HBV and HCV infection

No.	Author (year), ref.	Study design	Study subjects (numbers)	Frequency of intrahepatic (I) and peripheral (P) Tregs in patients and other findings*
1.	Peng et al (2008) <sup>5</sup>	CS	AHB (12) CHB (79)	P: = P: + P: initially low, + in the convalescent phase, normal upon resolution
2.	Xu et al (2006) <sup>6</sup>	L	AHB (16 blood samples) CHB (76 blood samples, 13 liver tissues) CSHB (29 blood samples, 9 liver tissues)	I: +; P: + I: ++; P: ++
3.	Wang et al (2017) <sup>7</sup>	CS	CHB (43)	I: +
4.	Stoop et al (2008) <sup>8</sup>	CS	CHB (32)	I: +, a higher proportion of Tregs in aetiots with a high viral load
5.	Shen et al (2015) <sup>9</sup>	CS	CHB (44)	I: +; P: +
6.	Niu et al (2011) <sup>10</sup>	CS	HBV-related ACLF (32) CHB liver failure (26) HBV-related ACLF (31)	I: ++; P: ++ I: + I: +, higher IL-17/FoxP3 ratio than the CHB liver failure group
7.	El-Badawy et al (2012) <sup>11</sup>	CS	CHB (59)	P: +
8.	Feng et al (2015) <sup>12</sup>	CS	CHB (96)	P: +
9.	Lin et al (2007) <sup>13</sup>	CS	CHB (79)	P: +
10.	Nan et al (2010) <sup>14</sup>	CS	CHB (39)	P: +, correlated positively with HBV DNA load
11.	Su et al (2013) <sup>15</sup>	CS	CHB (70)	P: +
12.	Yu et al (2014) <sup>16</sup>	CS	CHB (70)	P: ++
13.	Li et al (2014) <sup>17</sup>	CS	HBV-associated liver cirrhosis (28) CHB (26)	P: +
14.	Yang et al (2007) <sup>18</sup>	CS	CHB (65)	P: +
15.	Stoop et al (2005) <sup>19</sup>	CS	CHB (50)	P: +
16.	Li et al (2012) <sup>20</sup>	CS	CHB (77)	P: +
17.	Liang et al (2014) <sup>21</sup>	CS	HBV-related ACLF (18), CHB (18)	P: +, a lower Treg/Th17 ratio indicated more liver injury and fibrosis progression
18.	Zhai et al (2011) <sup>22</sup>	CS	HBV-related ACLF (30), CHB (30)	P: +, an increased Treg/Th17 ratio was associated with the survival of ACLF patients
19.	Zhang et al (2013) <sup>23</sup>	CS	HBV-related ACLF (14), CHB (30)	P: +, Treg frequency was significantly lower in the remission stage of ACLF when compared with the progression stage of the CHB group
20.	Nan et al (2012) <sup>24</sup>	L	CHB, treated with telbivudine (28)	P: -, Tregs decline was in parallel with the decline in viral load and serum ALT normalization
21.	Stoop et al (2007) <sup>25</sup>	L	CHB, treated with adefovir dipivoxil (12)	P: -, adefovir induced viral load reduction results in a decline of Tregs
22.	Yu et al (2013) <sup>26</sup>	L	CHB, treated with entecavir, lamivudine and adefovir (44)	P: -, Treg/Th17 ratio was dramatically declined in complete-responders
23.	Xu et al (2012) <sup>27</sup>	L	CHB, treated with IFN- $\alpha$ (47)	P: -
24.	Yang et al (2017) <sup>28</sup>	L	CHB, treated with telbivudine (27)	P: -, Tregs frequency was positively correlated with HBeAg level
25.	Zhang et al (2010) <sup>29</sup>	L	Patients seropositive for HBeAg, treated with entecavir	P: -, significant reduction of Treg/Th17 ratio
26.	Sprengers et al (2007) <sup>30</sup>	CS	Patients positive for HBeAg, treated with Peg-IFN- $\alpha$	P: + in non responders, - in responders
27.	Heeg et al (2009) <sup>31</sup>	CS	AHC (10), some patients received IFN+RBV CHC (15)	P: + (short-lived) P: +
28.	Smyk-Pearson et al (2008) <sup>32</sup>	L	AHC, treatment naive (27)	P: +, the resolution of disease was associated with a relative loss of functional suppression
29.	Accapezzato et al (2004) <sup>33</sup>	CS	CHC (47)	I: +
30.	Claassen et al (2010) <sup>34</sup>	CS	CHC (8)	I: +, Treg were more numerous in livers with limited fibrosis
31.	Amoroso et al (2012) <sup>35</sup>	CS	CHC (30)	I: +, intrahepatic Tregs was associated with high levels of effector T cells in the peripheral blood and lower activity of hepatitis
32.	Sturm et al (2010) <sup>37</sup>	CS	CHC (20)	I: +, accumulation of CD4 <sup>+</sup> FoxP3 <sup>+</sup> Treg cells in necro-inflammatory areas, in contact with CD8 <sup>+</sup> T cells
33.	Ward et al (2007) <sup>34</sup>	CS	CHC (28)	I: +
34.	Hashemipoor et al (2010) <sup>38</sup>	CS	CHC (20)	P: +
35.	Wang et al (2010) <sup>39</sup>	CS	CHC (31)	P: +, the increased Tregs were associated with HCV genotype 1b overexpression of TLR 2 and 4
36.	Bolacchi et al (2006) <sup>40</sup>	CS	CHC, treatment naive patients without liver cirrhosis (37); 16 had persistently normal ALT, 21 had persistently abnormal ALT	P: +, no significant differences of Tregs level in patients with persistently normal and elevated ALT

Table 1. The study of Tregs frequency in HBV and HCV infection (continued)

No.	Author (year), ref.	Study design	Study subjects (numbers)	Frequency of intrahepatic (I) and peripheral (P) Tregs in patients and other findings*
37.	Itoe et al (2009) <sup>41</sup>	CS	CHC (36)	P: +
38.	Tseng et al (2012) <sup>42</sup>	CS	CHC (57)	P: +, CHC patients with inflammation showed enhanced immunosuppressive function of Tregs
39.	Yoshizawa et al (2010) <sup>43</sup>	CS	HCV-infected patients (173); 76 CHC, 40 liver cirrhosis, 57 HCC	P: +, Tregs were not increased with the progression of fibrosis or the grade of inflammations
40.	Ferri et al (2011) <sup>44</sup>	CS	CHC (51 blood samples, 16 liver tissues)	I: + in half of liver samples, not detected in another half
41.	Ebinuma et al (2008) <sup>45</sup>	CS	HCC (23 blood samples)	P: +, circulating Tregs did not correlate with intrahepatic Foxp3
42.	Cabrera et al (2004) <sup>46</sup>	CS	ESLD (16 blood samples)	P: ++
43.	Keoshkerian et al (2016) <sup>47</sup>	L	CHC (14)	P: +
		CS	CHC (30)	P: +
		L	Injecting drug users were followed from uninfected status to incident infection (17)	Subjects who cleared the virus had HCV-specific CD4+ T-cell responses dominated by effector T cells and produced higher levels of IFN- $\gamma$
44.	Manigold et al (2006) <sup>48</sup>	CS	CHC (15)	P: +
45.	Akiyama et al (2010) <sup>49</sup>	L	Chimpanzees (16); HCV-naive (2), HCV-recovered (8), persistently HCV-infected (6)	P: +, the frequency of Tregs and the extent of suppression was as high in spontaneously HCV-recovered chimpanzees as in persistently HCV-infected chimpanzees
46.	Claassen et al (2011) <sup>50</sup>	L	CHC, treated with Peg-IFN- $\alpha$ and ribavirin (20)	I: +, Treg ratio was inversely proportional to viral decline in the SVR group
		L	CHC, treated with IFN- $\alpha$ and ribavirin (22)	I: + upon treatment administration in about 50% of CHC patients. After cessation of therapy, Treg remained above baseline
47.	Carpentier et al (2009) <sup>51</sup>	L	CHC, had undergone liver transplantation (30); 10 had stable HCV-negative and normal histological findings, 20 had recurrent CHC	P: = I: + at 5 years after liver transplantation, Tr1 cells were enhanced in patients with CHC recurrence
48.	Chalupa et al (2016) <sup>52</sup>	L	CHC, treated with IFN- $\alpha$ -based therapy (31)	P: +
49.	Hao et al (2014) <sup>53</sup>	L	CHC, treated with Peg-IFN- $\alpha$ 2a and ribavirin (114)	P: - in patients with RVR and EVR, = in patients with NR
50.	Kanto et al (2012) <sup>54</sup>	L	CHC, treated with Peg-IFN- $\alpha$ 2b and ribavirin (67)	P: + in SVR patients
51.	Li et al (2016) <sup>55</sup>	L	CHC, treated with IFN- $\alpha$ and RBV in vitro (105)	P: -
52.	Tseng et al (2017) <sup>56</sup>	L	CHC, treated with Peg-IFN- $\alpha$ 2a plus RBV or Peg-IFN- $\alpha$ 2b plus RBV (30)	P: - regardless of the treatment response
53.	Burton et al (2008) <sup>57</sup>	L	CHC, treated with Peg-IFN- $\alpha$ 2a plus RBV (62)	P: =
54.	Soldevila et al (2011) <sup>58</sup>	L	CHC, treated with Peg-IFN- $\alpha$ 2a and ribavirin (35)	P: NR patients had a higher Tregs percentage than SVR patients
55.	Langhans et al (2017) <sup>59</sup>	L	CHC, treated with DAA only or DAA plus IFN/RBV (26)	P: + in both treatment groups

\* +: the level of Tregs in study subjects increased or higher than that in healthy subjects (basal rate); -: the level of Tregs in study subjects is comparable to that in healthy subjects (basal rate); ACLF: acute-on-chronic liver failure; AHB: acute hepatitis B; AHC: acute hepatitis C; ALT: alanine transaminase; CHB: chronic hepatitis B; CHC: chronic hepatitis; CS: cross-sectional; CSHB: Chronic severe hepatitis B; ESLD: end-stage liver disease; EVR: early virological response; HCC: hepatocellular carcinoma; IFN: interferon; L: longitudinal; NR: no response; RBV: ribavirin; RVR: rapid virological response; SVR: sustained virological response; TLR: Toll-like receptor.



HBV: hepatitis B virus; HCV: hepatitis c virus; NHL: non-Hodgkin lymphoma; IHD: inflammatory heart disease

**Figure 1. The workflow of systematic search and analysis**

longitudinal studies, the follow up time is considered sufficient. All the studies clearly defined the criteria for inclusion. Study subjects and setting were described in detail and the measurements were performed according to the standards methods. The accurate measurements together with the appropriate use of statistical analysis resulting in valid and reliable results of the reviewed studies. Unfortunately, confounding factors and strategies to deal with them were not elaborated in detail, perhaps due to the complexity of immunological responses in HBV and HCV infection as well as the extent of biological variations amongst study subjects.

Chronic infection with HBV and HCV may cause immune-mediated liver injury that leads to liver cirrhosis, hepatocellular carcinoma, and liver failure. Until now, not all of chronic hepatitis B and C patients can be cured. Currently available treatments may slow down the progressivity of the illness, decrease the viral load and ease the symptoms but the viral clearance may not be completely achieved. The available direct-acting antiviral drugs are well tolerated and cause sustained virological response in most patients with chronic

hepatitis C. However, treatment failure may happen in some patients due to the lack of adherence and drug-to-drug interactions. If the infection persists, a constant exposure to the virus antigens will provoke the immune response and sooner or later, liver transplantation is the only solution for patients with irreversible liver damage. The limited liver donors and the continuing increase of demands cause more patients left untreated. Therefore, understanding immunological aspects of HBV and HCV infection is important to find a way to improve patient care.

The main immunological response to HBV and HCV infection is performed by a subset of white blood cells called T lymphocytes (T cells). An adequate response of T cells is necessary for spontaneous resolution during acute infection and for preventing permanent chronic infection. Even though T cells frequency correlates inversely with the viral load, T cells may contribute to liver damage through unknown mechanisms.<sup>60</sup> It has been argued that liver damage in chronic hepatitis patients was due to proinflammatory cytokines produced by non-specific T cells during the

viral clearance from liver cells. Therefore, it can be assumed that the key to cure chronic hepatitis B and C is by restoring an effective T cells response.

The roles of Tregs in chronicity of HBV infection have been confirmed. Increased Tregs correlate with poor short-term outcomes in HBV-related acute-on-chronic liver failure patients.<sup>9</sup> While there is clinical evidence of a relevant role for Tregs in chronic HCV-infected patients, based on their increased number and function; mechanisms underlying such phenomena are still poorly understood.<sup>61</sup> This present review shows that the frequency of Tregs is associated with the chronicity of HBV and HCV infection. The increase of intrahepatic Tregs during chronic infection may be directed to protecting liver tissue from immune-mediated injury whereas the decrease of Tregs frequency may be influenced by the treatment given; i.e. the type and duration of treatment. Thus, analyzing Tregs frequency during the course of hepatitis B and C may give a valuable information to clinicians with regards to disease chronicity, the severity of the illness, and response to treatment.

## CONCLUSION

The role of Tregs for suppression of immune responses during HBV and HCV infection is vital to prevent immune-mediated liver injury. On the other hand, the suppression of immune responses in fighting viral replication poses a detrimental effect as this causes persistent infection. These contrary effects of Tregs may influence the clinical course of HBV and HCV-infected patients. This review shows that infection with HBV and HCV promotes the increase of Tregs in patients' blood and hepatocytes whereas the treatments may decrease Tregs levels. Further studies are needed to examine the dynamics of Tregs during the course of infection and its relation with clinical outcomes. Such studies are important to understand the immunologic properties of Tregs and may be developed as a novel strategy to combat hepatitis B and C.

## ACKNOWLEDGMENT

The author thanks Dr Atik Susianto for his help in literature search and proofreading the manuscript.

## Funding

This work is supported by Universitas Sebelas Maret (non-tax revenue) grant.

## REFERENCES

1. World Health Organization. Global hepatitis report 2017 [serial online] [cited 2018 April 10]. Available from: <http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=05C90CB9B43F9C57565ECBFB53C870DA?sequence=1>.
2. Bennett H, Waser N, Johnston K, Kao JH, Lim YS, Duan ZP, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. *Hepatol Int* 2015;9:378–90.
3. Jung MK, Shin EC. Regulatory T Cells in Hepatitis B and C Virus Infections. *Immune Netw* 2016;16:330–6.
4. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;339:b2700.
5. Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z. Circulating CD4+CD25+ regulatory T cells correlate with chronic hepatitis B infection. *Immunology* 2008;123:57–65.
6. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. *J Immunol* 2006;177:739–47.
7. Wang H, Wu B, Li L, Hu L, Lin J, Jiang C, et al. Hepatic expansion of virus-specific CD8+BTLA+ T cells with regulatory properties in chronic hepatitis B virus infection. *Cell Immunol* 2017;311:36–45.
8. Stoop JN, Claassen MA, Woltman AM, Binda RS, Kuipers EJ, Janssen HL, et al. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. *Clin Immunol* 2008;129:419–27.
9. Shen C, Yan WZ, Zhao CY, Che HH, Liu XY, Liu ZZ, et al. Increased CD4+CD25+ regulatory T cells correlate with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients. *J Microbiol Immunol Infect* 2015;48:137–46.
10. Niu Y, Liu H, Yin D, Yi R, Chen T, Xue H, et al. The balance between intrahepatic IL-17(+) T cells and Foxp3(+) regulatory T cells plays an important role in HBV-related end-stage liver disease. *BMC Immunol* 2011;12:47.
11. El-Badawy O, Sayed D, Badary MS, Abd-Alrahman ME, El-Feky MA, Thabit AG. Relations of regulatory T cells with hepatitis markers in chronic hepatitis B virus infection. *Hum Immunol* 2012;73:335–41.
12. Feng H, Yin J, Han YP, Zhou XY, Chen S, Yang L, et al. Regulatory T cells and IL-17(+) T helper cells enhanced in patients with chronic hepatitis B virus infection. *Int J Clin Exp Med* 2015;8:8674–85.
13. Lin CY, Tsai MC, Huang CT, Hsu CW, Tseng SC, Tsai IF, et al. Liver injury is associated with enhanced regulatory T-cell activity in patients with chronic hepatitis B. *J Viral Hepat* 2007;14:503–11.
14. Nan XP, Zhang Y, Yu HT, Li Y, Sun RL, Wang JP, et al. Circulating CD4+CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. *Viral Immunol* 2010;23:63–70.
15. Su ZJ, Yu XP, Guo RY, Ming DS, Huang LY, Su ML, et al. Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B. *Diagn Microbiol Infect Dis* 2013;76:437–44.

16. Yu X, Guo R, Ming D, Su M, Lin C, Deng Y, et al. Ratios of regulatory T cells/T-helper 17 cells and transforming growth factor-beta/interleukin-17 to be associated with the development of hepatitis B virus-associated liver cirrhosis. *J Gastroenterol Hepatol* 2014;29:1065–72.
17. Li J, Shi J, Ren W, Wu W, Chen Z. Regulatory role of CD4(+)CD25 (+)Foxp3 (+) regulatory T cells on IL-17-secreting T cells in chronic hepatitis B patients. *Dig Dis Sci* 2014;59:1475–83.
18. Yang G, Liu A, Xie Q, Guo TB, Wan B, Zhou B, et al. Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. *Int Immunol* 2007;19:133–40.
19. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. *Hepatology* 2005;41:771–8.
20. Li J, Qiu SJ, She WM, Wang FP, Gao H, Li L, et al. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. *PLoS One* 2012;7:e39307.
21. Nan XP, Zhang Y, Yu HT, Sun RL, Peng MJ, Li Y, et al. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. *Viral Immunol* 2012;25:21–8.
22. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. *Virology* 2007;361:141–8.
23. Yu XP, Guo RY, Su ML, Ming DS, Lin CZ, Deng Y, et al. Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment. *Hepat Mon* 2013;13:e15332.
24. Xu HT, Xing TJ, Li H, Ye J. Association of T regulatory cells with natural course and response to treatment with interferon-alpha in patients with chronic hepatitis B infection. *Chin Med J (Engl)* 2012;125:1465–8.
25. Yang X, Li J, Liu J, Gao M, Zhou L, Lu W. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study. *Medicine (Baltimore)* 2017;96:e7064.
26. Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, Wang FS. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. *PLoS One* 2010;5:e13869.
27. Sprengers D, Stoop JN, Binda RS, Kusters JG, Haagmans BL, Carotenuto P, et al. Induction of regulatory T-cells and interleukin-10-producing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B. *Antivir Ther* 2007;12:1087–96.
28. Heeg MH, Ulsenheimer A, Gruner NH, Zachoval R, Jung MC, Gerlach JT, et al. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. *Gastroenterology* 2009;137:1280–1288.e1281–6.
29. Smyk-Pearson S, Golden-Mason L, Klarquist J, Burton JR, Jr., Tester IA, Wang CC, et al. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. *J Infect Dis* 2008;197:46–57.
30. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. *J Clin Invest* 2004;113:963–72.
31. Claassen MA, de Kneegt RJ, Tilanus HW, Janssen HL, Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. *J Hepatol* 2010;52:315–21.
32. Amoroso A, D'Amico F, Consolo M, Skarmoutsou E, Neri S, Dianzani U, et al. Evaluation of circulating CD4+CD25+ and liver-infiltrating Foxp3+ cells in HCV-associated liver disease. *Int J Mol Med* 2012;29:983–8.
33. Sturm N, Thelu MA, Camous X, Dimitrov G, Ramzan M, Dufeu-Duchesne T, et al. Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. *J Hepatol* 2010;53:25–35.
34. Ward SM, Fox BC, Brown PJ, Worthington J, Fox SB, Chapman RW, et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. *J Hepatol* 2007;47:316–24.
35. Hashempoor T, Bamdad T, Merat S, Janzamin E, Nemati L, Jabbari H, et al. Expansion of CD4+ CD25+ FoxP3+ regulatory T cells in chronic hepatitis C virus infection. *Iran J Immunol* 2010;7:177–85.
36. Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, et al. Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. *APMIS* 2010;118:261–70.
37. Bolacchi F, Sinistro A, Ciapriani C, Demin F, Capozzi M, Carducci FC, et al. Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. *Clin Exp Immunol* 2006;144:188–96.
38. Itose I, Kanto T, Kakita N, Takebe S, Inoue M, Higashitani K, et al. Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis. *J Viral Hepat* 2009;16:844–52.
39. Tseng KC, Ho YC, Hsieh YH, Lai NS, Wen ZH, Li C, et al. Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. *J Gastroenterol* 2012;47:823–33.
40. Yoshizawa K, Abe H, Kubo Y, Kitahara T, Aizawa R, Matsuoka M, et al. Expansion of CD4(+)CD25(+)FoxP3(+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. *Hepatol Res* 2010;40:179–87.
41. Ferri S, Lalanne C, Lanzoni G, Bassi M, Asioli S, Cipriano V, et al. Redistribution of regulatory T-cells across the evolving stages of chronic hepatitis C. *Dig Liver Dis* 2011;43:807–13.
42. Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, et al. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. *J Virol* 2008;82:5043–53.
43. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. *Hepatology* 2004;40:1062–71.
44. Keoshkerian E, Hunter M, Cameron B, Nguyen N, Sugden P, Bull R, et al. Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection. *J Viral Hepat* 2016;23:985–93.
45. Manigold T, Shin EC, Mizukoshi E, Mihalik K, Murthy KK, Rice CM, et al. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. *Blood* 2006;107:4424–32.
46. Akiyama M, Ichikawa T, Miyaaki H, Motoyoshi Y, Takeshita S, Ozawa E, et al. Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C. *Intervirol* 2010;53:154–60.

47. Claassen MA, de Kneegt RJ, Janssen HL, Boonstra A. Retention of CD4<sup>+</sup> CD25<sup>+</sup> FoxP3<sup>+</sup> regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans. *J Virol* 2011;85:5323–30.
48. Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, et al. Increased expression of regulatory T cells in recurrent hepatitis C after liver transplantation. *Am J Transplant* 2009;9:2102–12.
49. Chalupa P, Davidova A, Beran O, Arientova S, Bostik P, Kapla J, et al. Effect of antiviral treatment of chronic hepatitis C on the frequency of regulatory T cells, T-cell activation, and serum levels of TGF-beta. *APMIS* 2016;124:711–8.
50. Hao C, Zhou Y, He Y, Fan C, Sun L, Wei X, et al. Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C. *Immunology* 2014;143:531–8.
51. Kanto T, Inoue M, Oze T, Miyazaki M, Sakakibara M, Kakita N, et al. Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients. *J Gastroenterol* 2012;47:169–78.
52. Li Z, Ping Y, Yu Z, Wang M, Yue D, Zhang Z, et al. Dynamic changes in CD45RA(-)Foxp3(high) regulatory T-cells in chronic hepatitis C patients during antiviral therapy. *Int J Infect Dis* 2016;45:5–12.
53. Tseng KC, Ho YC, Tseng CW, Tseng LH, Hsieh YH, Chang TT, et al. Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin. *Int J Infect Dis* 2017;58:8–17.
54. Burton JR, Jr., Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, et al. Prospective analysis of effector and regulatory CD4<sup>+</sup> T cells in chronic HCV patients undergoing combination antiviral therapy. *J Hepatol* 2008;49:329–38.
55. Soldevila B, Alonso N, Martinez-Arconada MJ, Morillas RM, Planas R, Sanmarti AM, et al. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment. *J Viral Hepat* 2011;18:384–92.
56. Langhans B, Nischalke HD, Kramer B, Hausen A, Dold L, van Heteren P, et al. Increased peripheral CD4<sup>+</sup> regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. *J Hepatol* 2017;66:888–96.
57. Liang XS, Li CZ, Zhou Y, Yin W, Liu YY, Fan WH. Changes in circulating Foxp3(+) regulatory T cells and interleukin-17-producing T helper cells during HBV-related acute-on-chronic liver failure. *World J Gastroenterol* 2014;20:8558–71.
58. Zhai S, Zhang L, Dang S, Yu Y, Zhao Z, Zhao W, et al. The ratio of Th-17 to Treg cells is associated with survival of patients with acute-on-chronic hepatitis B liver failure. *Viral Immunol* 2011;24:303–10.
59. Zhang GL, Xie DY, Lin BL, Xie C, Ye YN, Peng L, et al. Imbalance of interleukin-17-producing CD4 T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acute-on-chronic liver failure. *J Gastroenterol Hepatol* 2013;28:513–21.
60. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. *Immunity* 2014;40:13–24.
61. Fernandez-Ponce C, Dominguez-Villar M, Aguado E, Garcia-Cozar F. CD4<sup>+</sup> primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells. *PLoS One* 2014;9:e85191.